CLINICAL USE

Fibrinolytic agent: Thrombosed arteriovenous shunts and intravenous cannulas Treatment of thromboembolic occlusive vascular disease, e.g. DVT, PE, peripheral vascular occlusion

DOSE IN NORMAL RENAL FUNCTION

Lock: 5000–250 000 IU for 30 minutes – 2 hours Infusion: 5000–250 000 IU over 30 minutes – 48 hours, depending on local protocol

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 33 000–54 000
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : No data
  • %Excreted unchanged in urine &nbsp &nbsp : Low
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp : No data
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 20 minutes/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp: Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    2 mL of sodium chloride 0.9%

    Route

    Rate of Administration

    Various

    Comments

    OTHER INFORMATION

    Doses from Kumwenda M, Cornall A, Corner L, et al. Urokinase for dysfunctional haemodialysis catheters. Br J Renal Med. 2005; 10(3): 10–11 Can also be given during dialysis Care in patients with uraemic coagulopathies or bleeding diatheses Some units mix 5000 IU with 1.5 mL heparin 1000 u/mL .